Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients

NCT02654145 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

145

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: Mepolizumab 100mg SC
DRUG: Albuterol/salbutamol MDIs
DRUG: Omalizumab

Sponsor

GlaxoSmithKline